WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...
In July, the US Food and Drug Administration (FDA) approved a new blood-based test to screen for colorectal cancer (CRC). The FDA's approval of Shield (Guardant Health) marks a notable achievement, as ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results